GlassScriptPhysician profile
Justin M Green
NPI 1639525884
$8,886.46
in general payments reported to CMS, 2019-2025
52 companies · $1,102 in 2025
The $1,102 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $850 · 2021: $1,521 · 2022: $1,947 · 2023: $1,703 · 2024: $1,086 · 2025: $1,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,769 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,768.90 |
| Education | $122.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,619.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $991.74 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $855.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.90 | 2019-2023 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Abbvie INC. | $591.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $395.50 | 2019-2025 | Lokelma, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $236.39 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $223.28 | 2020-2025 | Repatha, Otezla, Evenity |
| Abbott Laboratories | $217.71 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $214.44 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $200.48 | 2021-2022 | |
| Edwards Lifesciences Corporation | $197.97 | 2022-2024 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $177.18 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Exact Sciences Corporation | $164.39 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.91 | 2019-2025 | Xifaxan |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.